Industry News
In Patients With Drug-Resistant Prostate Cancer, New Drug Extends Survival
Feb 02, 2012
A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show. The drug is designed to block a type of cellular receptor that drives progression of prostate cancer... Read More
Breast Cancer Surgery Often Repeated To Take Out More Tissue
Feb 01, 2012
22.9% of breast cancer patients who undergo partial mastectomies need further operations to remove more tissue, researchers reported in JAMA (Journal of the American Medical Association)... Read More
Erivedge - Treatment For Most Common Form Of Skin Cancer
Feb 01, 2012
Basal cell carcinoma is a form of skin cancer caused by regular sun exposure, or other ultraviolet radiation, which starts in the top layer of the skin (epidermis), is usually painless and grows slowly. The U.S. Food and Drug Administration just approved a new drug named Erivedge (vismodegib) for the treatment of adult patients with basal cell carcinoma, the most common type of skin cancer... Read More
Erivedge - Treatment For Most Common Form Of Skin Cancer
Feb 01, 2012
Basal cell carcinoma is a form of skin cancer caused by regular sun exposure, or other ultraviolet radiation, which starts in the top layer of the skin (epidermis), is usually painless and grows slowly. The U.S. Food and Drug Administration just approved a new drug named Erivedge (vismodegib) for the treatment of adult patients with basal cell carcinoma, the most common type of skin cancer... Read More
Improved Detection Of Colorectal Cancer By Flexible Sigmoidoscopy
Feb 01, 2012
Repeated screening by flexible sigmoidoscopy (FSG) increased the detection of colorectal cancer or advanced adenoma in women by one-fourth and in men by one-third, according to a study published Jan. 31 in the Journal of the National Cancer Institute... Read More
Preclinical Study Identifies New Target For Cancer Therapy
Feb 01, 2012
Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors. Called tryptophan 2,3-dioxygenase or TDO, the enzyme works by depriving immune cells of tryptophan, an amino acid essential to their activity... Read More
Improved Detection Of Colorectal Cancer By Flexible Sigmoidoscopy
Feb 01, 2012
Repeated screening by flexible sigmoidoscopy (FSG) increased the detection of colorectal cancer or advanced adenoma in women by one-fourth and in men by one-third, according to a study published Jan. 31 in the Journal of the National Cancer Institute... Read More
FDA Approves Drug For Common Skin Cancer
Feb 01, 2012
On Monday, the US Food and Drug Administration approved a new type of drug to treat adult patients with advanced basal-cell carcinoma, the most common type of skin cancer. The drug's generic name is vismodegib and was developed by the US part of Roche Holding AG. It will be sold in the US by Roche's South San Francisco-based Genentech under the brand name Erivedge... Read More
Alcohol Consumption And Risk Of Colon Cancer In People With A Family History Of Such Cancer
Feb 01, 2012
A study based on more than 87,000 women and 47,000 men in the Nurses' Health Study and the Health Professionals Follow-up Study, looks at whether there is a link between colon cancer and alcohol, and if so at what level of consumption, and the importance of a family history of the disease. A total of 1,801 cases of colon cancer were diagnosed during follow-up from 1980 onwards... Read More
Genetic Breakthrough For Brain Cancer In Children
Feb 01, 2012
An international research team led by the Research Institute of the McGill University Health Centre (RI MUHC) has made a major genetic breakthrough that could change the way pediatric cancers are treated in the future... Read More
Previous Page Next Page